Published in Leuk Res Rep on July 04, 2013
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell (2011) 5.28
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
The myeloproliferative disorders. N Engl J Med (2006) 4.30
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood (2010) 2.61
New mutations and pathogenesis of myeloproliferative neoplasms. Blood (2011) 2.53
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood (2007) 2.44
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood (2011) 1.40
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood (2007) 1.23
Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes Cancer (2010) 0.93
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia. Semin Hematol (2015) 0.86
A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. Leuk Res Rep (2014) 0.75